GALDY (Galderma Group AG) Marketable Securities: $0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GALDY Galderma Group AG GALDY
21 GF Score
Price $39.88
View Full Analysis

What is Galderma Group AG Marketable Securities?

Galderma Group AG GALDY +1.89% 21 Marketable Securities is $0 Mil as of Jun. 2026. GuruFocus rates GALDY with a GF Score™ of 21/100.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Galderma Group AG's Marketable Securities for the quarter that ended in Jun. 2026 was $0 Mil.

Galderma Group AG's annual Marketable Securities increased from Dec. 2023 ($127 Mil) to Dec. 2024 ($175 Mil) and increased from Dec. 2024 ($175 Mil) to Dec. 2025 ($455 Mil).

Galderma Group AG  (OTCPK:GALDY) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Galderma Group AG Marketable Securities Related Terms

Galderma Group AG Marketable Securities Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Marketable Securities Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
2.70 0.20 127.20 175.00 455.00

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Marketable Securities Get a 7-Day Free Trial 0.00 175.00 0.00 455.00 0.00
GALDY
21GF Score
Galderma Group AG GALDY
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galderma Group AG Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0 Mil mean?
Galderma Group AG (GALDY) has a Marketable Securities of $0 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Galderma Group AG and its competitors.
Is Galderma Group AG's Marketable Securities too high?
Galderma Group AG's current Marketable Securities is $0 Mil. Overall, Galderma Group AG has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Marketable Securities compare to ZTS and UTHR?
Galderma Group AG's Marketable Securities of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Galderma Group AG and its competitors. Galderma Group AG's current Marketable Securities is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (GALDY) has a current Marketable Securities of $0 Mil. The current Marketable Securities is $0 Mil. Galderma Group AG's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Galderma Group AG (GALDY), the current Marketable Securities is $0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma Group AG is a pure-play dermatology company headquartered in Switzerland and listed on the SIX Swiss Exchange. It operates across three main segments: injectable aesthetics, including neuromodulators such as Botox rival Dysport and fillers like Restylane and Sculptra; dermatological skincare, marketed under brands including Cetaphil, Alastin, and Benzac; and therapeutic dermatology, with treatments such as Soolantra, Epiduo, and Aklief for acne, rosacea, and other skin conditions. The company sells to dermatologists, aesthetic practitioners, physicians, and consumers through both prescription and over-the-counter channels. It operates in around 90 countries, with the United States as its largest market, followed by Europe, Asia-Pacific, and Latin America. Revenue comes from product sales across these segments, with injectable aesthetics and dermatological skincare representing the largest contributors. Galderma invests significantly in research and development and maintains manufacturing and R&D sites internationally.
21GF Score

Get the complete analysis for GALDY

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.88
Price